- Business Wire•yesterdayQuintilesIMS Institute Report Identifies Nine Evidence-based Approaches to Transform Drug Development and Commercialization
Life sciences companies increasingly are seeking new models to connect expanding sets of disparate, non-identified patient-level data streams to better develop and commercialize next-generation medicines. The need for practical, evidence-based approaches is especially acute at a time when scientific advances, the growing need for new medicines, and constrained budgets for healthcare and other social ...
- Business Wire•9 days ago
Quintiles IMS Holdings, Inc. will issue its third-quarter 2016 financial results before the market opens on Wednesday, November 2, 2016. The earnings release and accompanying financial information will be posted on the QuintilesIMS Investor Relations website at http://ir.quintilesims.com.
- Business Wire•10 days ago
QuintilesIMS announced today that it has been awarded the 2016 Eagle Award from the Society for Clinical Research Sites for the fourth consecutive year. Presented during the annual SCRS Site Solutions Summit, the site-nominated award recognizes contract research organizations and biopharmaceutical sponsors dedicated to building positive relationships with research sites through leadership, professionalism ...
Quintiles IMS Holdings, Inc. (Q)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||71.95 x 100|
|Ask||71.98 x 300|
|Day's Range||71.31 - 72.27|
|52wk Range||55.01 - 81.45|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.60|
|Avg Vol (3m)||1,144,996|
|Dividend & Yield||N/A (N/A)|